C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
VREOF US MSO

Vireo Growth

OTCMKTS · VREOF

Cannabis operator with dispensaries and cultivation across multiple US states.

$8.92
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
58/100 composite
Fundamentals88
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Vireo Growth earns a Neutral rating, with a 57.5 composite score and 2/5 conviction. Fundamentals provide the decisive support at 88, led by top-tier revenue growth, an 82.7 gross-margin subscore, an 89.7 operating-margin subscore, and a 90 cash-runway subscore reflecting positive EBITDA alongside a net loss. Regulatory contributes a middling 49, combining a 50 jurisdiction posture and 80 enforcement subscore with a weak 25 cadence subscore. Market contributes 40 because no institutional quote is available, while editorial contributes 30 amid no recent newsroom or brief activity. The resulting profile places Vireo firmly in the Neutral band: operating performance is strong, but regulatory cadence, market visibility, and editorial momentum dilute conviction.

Licensed fundamentals data show year-over-year revenue growth above 330%, a gross margin just under 50%, and an operating margin near 17%. Those figures explain the fundamentals pillar’s clear lead and indicate substantial operating leverage. EBITDA stands near $45 million, but net income remains a loss of roughly $82 million, preserving the stretched financial condition despite positive operating earnings. Market capitalization is approximately $491 million. Primary regulatory filings show no events during the latest 90-day period and only one during the latest 180-day period, with the most recent filing dated June 18, 2026. The absence of enforcement hits supports the regulatory pillar, but sparse filing activity constrains its overall contribution. Institutional pricing feeds provide no current quote, and CIN newsroom coverage records no newsroom or brief hits, leaving both market and editorial pillars without incremental support.

The forward case rests on fundamentals converting exceptional revenue growth and strong margins into improved bottom-line performance. Positive EBITDA already demonstrates operating earnings capacity, while the near-50% gross margin and high-teens operating margin provide the strongest basis for further earnings conversion. A sustained reduction in the roughly $82 million net loss would strengthen the leading pillar, improve the stretched financial profile, and create the clearest route above Neutral. The single most important signal to watch is whether the next primary regulatory filing shows that strong revenue growth and operating margins are translating into a materially narrower net loss.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
207 SOUTH 9TH STREET, MINNEAPOLIS, MN, 55402
Phone
604-617-5421
CEO
John Mazarakis
CFO
Tyson Macdonald
SEC CIK
1771706
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$490.7M
Enterprise value
$769.4M
Price to book
1.67
Price to sales
1.40
EV / EBITDA
40.49
Revenue (TTM)
$350.5M
Gross profit (TTM)
$174.0M
EBITDA
$45.2M
Operating margin
16.7%
Profit margin
-23.4%
Rev growth YoY
333.5%
Return on equity
-47.5%
Return on assets
2.6%
EPS (TTM)
$-2.70
EPS est. current year
$0.20
Wall St. target price
$45.00
Shares outstanding
48.5M
Insider ownership
33.2%
Institutional ownership
7.8%
Beta
0.07
Full-time employees
520
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Vireo Growth (VREOF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Vireo Growth (VREOF), a cannabis-sector equity listed on OTCMKTS in the US MSO category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (3 bullish signals, 1 bearish signal.)

Cannabis operator with dispensaries and cultivation across multiple US states.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for VREOF are maintained by Cannabis Investor News and refreshed throughout the trading day.